|
Prior to joining Texas Pacific Group Ventures in 2004, Dr. Geoff Duyk served on the Board of Directors and was President of Research & Development at Exelixis where he led a 550+ person group focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals. As Vice President of Genomics at Millennium, Geoff was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the human genome project.
Dr. Duyk serves on the Board of Directors of Avidia, Macrogenics, Open Biosystems, Aerie, FoldRx, Amyris and Replidyne. He is a counsel member of the National Human Genome Research Institute at the National Institute of Health. He also serves on the Scientific Advisory Boards of the NHGRI DNA Sequencing Advisory Panel, Chair of the KOMP (Global Mouse TKO project), ESC (Expressed Sequenced Consortium), Co-Chair Advisory Panel Cancer Genome Project, Program in Genomics Applications (NHBLI); the Bioethics Advisory Group at Case Western Reserve University; the Spinal Muscular Atrophy Foundation; Jackson Laboratories - Bar Harbor Maine; Molecular Sciences Institute (UCB); WIL Laboratories; VLST; Avidia and FoldRx.
Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute.
| 